At present, what are the treatment methods of psoriasis and rheumatoid arthritis?

Psoriasis, also known as psoriasis, is a kind of recurrent and stubborn skin disease, and psoriatic arthritis not only leads to plaque lesions on the skin surface of patients, but also leads to joint pain and deformation, which is an immune disease In addition to adalimumab, aprost and tofatinib are very good drugs for psoriatic arthritis On the left is India generic, on the right is Bangladesh generic There are two specifications of 10mg and 30mg, which are boxed tablets Because of the special method of administration, the 10mg dose is not for the special population who need to reduce the dose, but for all patients in the early stage of taking an excessive dose As shown in Table 1, in the three clinical trials with the code of PSA, the 16 week ACR remission rate (efficacy evaluation index of American rheumatology Society) of apopst was significantly higher than that of placebo group, and the ACR20 even reached about 40%, which was a very good result As shown in Table 2, for the control of psoriasis, the proportion of people whose PASI index (psoriasis area and severity index) decreased by 75 in 16 weeks reached about 30%, and the sPGA clearance index (static physician overall assessment clearance index) also exceeded 20%, much higher than the placebo group In the course of use, patients can obviously feel less plaque on their body As a selective inhibitor of phosphodiesterase-4 (PDE-4), it is effective for psoriasis and arthritis psoriasis, including those patients who have previously used biological agents or conventional systemic drugs As a small molecular compound, it is easy to take orally, convenient for patients to take medicine, avoiding skin irritation and other adverse reactions caused by injection, and does not need to monitor laboratory indicators frequently Single administration, and the effect is not inferior to Sujin mAb, adalimumab (Xiumei), etanercept (En Li), infliximab and other biological agents, and significantly better than other traditional treatment drugs Clinical data showed that the severity of psoriasis of nails, scalp, palms and feet (hands and feet) was significantly improved after 16 weeks of treatment, which was maintained in the whole 52 weeks, making the patient's condition significantly and permanently improved The half-life of apopst is short, and the safety factor of treatment interruption is high Therefore, aprost can be used in patients with plaque psoriasis and arthrosis psoriasis who have no efficacy or contraindications in traditional systemic drug therapy, and in patients with poor efficacy or compliance with biological agents 5 mg regular tablets, 60 Tablets in a bottle, one month dosage For patients with rheumatoid arthritis who did not respond to conventional antirheumatic drugs, the rate of ACR20 (20% remission rate of American rheumatology Society) reached 69% at 6 months The acr70 (American rheumatology society 70% remission rate) was also 22% The placebo was no longer evaluated because the patient's condition had deteriorated significantly For patients with methotrexate ineffectiveness, the ACR20 of the combination therapy of tofetinib and methotrexate reached 50% at 6 months, double that of placebo 14% of acr70 For patients with TNF - α antibodies, such as sumac, infliximab and enalapril, the ACR20 and acr70 in the treatment combination of tofetinib and methotrexate for 6 months were up to 51% and 16% respectively, which was very remarkable It can be said that in rheumatoid arthritis, the therapeutic effect of topatinib is incomparable, even the effect of heavy bomb biological products such as adamumumab is not as good as topatinib In addition, tofetinib has a very good therapeutic effect on ankylosing spondylitis and alopecia areata.